New power wheelchair rule is official
This article was originally published in The Gray Sheet
Executive Summary
As of April 1, beneficiaries must meet face-to-face with a healthcare practitioner to receive a prescription for a power mobility device. The rule replaces CMS' former "bed-or-chair confined" criterion. According to CMS, the practitioner must also submit documentation from the beneficiary's medical history as evidence of the need for the device. The final rule differs from the interim final rule in that it gives a practitioner 45 days, rather than 30 days, to submit documentation to an equipment supplier after conducting the interview. During a September forum on the CMS decision, suppliers complained that the new prescription method was more complicated than the system it replaces (1"The Gray Sheet" Sept. 19, 2005, p. 9). The final rule also provides an add-on payment to practitioners for the work involved in compiling and transmitting the required documentation to the DME supplier...
You may also be interested in...
Power Wheelchair Suppliers Spar With CMS Over New Regs
Suppliers of power mobility equipment say CMS' new interim final rule on the devices creates a system that is more complicated than the one it replaces and should not be implemented until next April
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.